Our Reports
Automotive Reports Electronics & Semiconductor Telecom & IT Technology & IT Consumer Goods Healthcare Food & Beverages Chemical
Our Links
About Us Contact Us Press Release News Our Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com

Europe Rapid Acting Insulin Market By Product Type (Insulin Lispro, Insulin Aspart and Insulin Glulisine), By Indication (Type 2 Diabetes and Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

Published Date : 12-May-2021

Pages: 88

Formats: PDF

The Europe Rapid Acting Insulin Market would witness market growth of 5.2% CAGR during the forecast period (2021-2027). Rapid-acting insulins come in the form which can be easily absorbed by the body, without the need to break it down. With regular insulin, the body does the work of decreasing the insulin protein to a small size before it is ready for absorption and starts activating. The regular insulin can consume above 30 minutes from the time it is injected until it starts activating on cells. With rapid-acting insulins, this time becomes half, so there is less possibility of mistakes. It starts activating in a similar manner as naturally produced insulin does.

Insulin resistance is associated with a higher rate of blood pressure and coronary heart disorders. In multiple clinical trials on individuals with heart failure, the infusion of insulin, potassium, and glucose enhanced heart pumping function. Insulin compels the relaxation of muscles in the artery walls, hence accelerating blood flow. Various human studies revealed higher blood flow levels in the heart muscle after insulin administration. In a cell-based study, insulin improved the production and secretion of a compound which is essential for the creation of new blood vessels. Therefore, these positive outcomes of insulin would boost the demand for rapid-acting insulin in the upcoming years.

The Germany market dominated the Europe Type 1 Diabetes Market by Country in 2020, thereby, achieving a market value of $92.2 Million by 2027. The UK market is exhibiting a CAGR of 5.1% during (2021 - 2027). Additionally, The France market is poised to grow at a CAGR of 7.4% during (2021 - 2027).

Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine. Based on Indication, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: The Global Rapid Acting Insulin Market Size will Hit $11.4 Billion by 2027, at a CAGR of 5.6%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.

Scope of the Study

Market Segments Covered in the Report:

By Product Type

  • Insulin Lispro
  • Insulin Aspart
  • Insulin Glulisine

By Indication

  • Type 2 Diabetes
  • Type 1 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

  • Merck & Co., Inc.
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Adocia SA
  • Biocon Limited
  • Gan & Lee Pharmaceuticals
  • Geropharm LLC
  • Wockhardt Ltd.
  • MannKind Corporation
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Rapid Acting Insulin Market, by Product Type
1.4.2 Europe Rapid Acting Insulin Market, by Indication
1.4.3 Europe Rapid Acting Insulin Market, by Distribution Channel
1.4.4 Europe Rapid Acting Insulin Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)

Chapter 4. Europe Rapid Acting Insulin Market by Product Type
4.1 Europe Insulin Lispro Market by Country
4.2 Europe Insulin Aspart Market by Country
4.3 Europe Insulin Glulisine Market by Country

Chapter 5. Europe Rapid Acting Insulin Market by Indication
5.1 Europe Type 2 Diabetes Market by Country
5.2 Europe Type 1 Diabetes Market by Country

Chapter 6. Europe Rapid Acting Insulin Market by Distribution Channel
6.1 Europe Hospital Pharmacies Market by Country
6.2 Europe Drug Stores & Retail Pharmacies Market by Country
6.3 Europe Online Providers Market by Country

Chapter 7. Europe Rapid Acting Insulin Market by Country
7.1 Germany Rapid Acting Insulin Market
7.1.1 Germany Rapid Acting Insulin Market by Product Type
7.1.2 Germany Rapid Acting Insulin Market by Indication
7.1.3 Germany Rapid Acting Insulin Market by Distribution Channel
7.2 UK Rapid Acting Insulin Market
7.2.1 UK Rapid Acting Insulin Market by Product Type
7.2.2 UK Rapid Acting Insulin Market by Indication
7.2.3 UK Rapid Acting Insulin Market by Distribution Channel
7.3 France Rapid Acting Insulin Market
7.3.1 France Rapid Acting Insulin Market by Product Type
7.3.2 France Rapid Acting Insulin Market by Indication
7.3.3 France Rapid Acting Insulin Market by Distribution Channel
7.4 Russia Rapid Acting Insulin Market
7.4.1 Russia Rapid Acting Insulin Market by Product Type
7.4.2 Russia Rapid Acting Insulin Market by Indication
7.4.3 Russia Rapid Acting Insulin Market by Distribution Channel
7.5 Spain Rapid Acting Insulin Market
7.5.1 Spain Rapid Acting Insulin Market by Product Type
7.5.2 Spain Rapid Acting Insulin Market by Indication
7.5.3 Spain Rapid Acting Insulin Market by Distribution Channel
7.6 Italy Rapid Acting Insulin Market
7.6.1 Italy Rapid Acting Insulin Market by Product Type
7.6.2 Italy Rapid Acting Insulin Market by Indication
7.6.3 Italy Rapid Acting Insulin Market by Distribution Channel
7.7 Rest of Europe Rapid Acting Insulin Market
7.7.1 Rest of Europe Rapid Acting Insulin Market by Product Type
7.7.2 Rest of Europe Rapid Acting Insulin Market by Indication
7.7.3 Rest of Europe Rapid Acting Insulin Market by Distribution Channel

Chapter 8. Company Profiles
8.1 Merck & Co., Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.2 Sanofi S.A.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Product Launches and Product Expansions:
8.2.5.2 Approvals and Trials:
8.3 Novo Nordisk A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental & Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.3.5.2 Approvals and Trials:
8.3.5.3 Partnerships, Collaborations, and Agreements:
8.4 Eli Lilly and Company
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.4.5.2 Approvals and Trials:
8.4.5.3 Partnerships, Collaborations, and Agreements:
8.5 Adocia SA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expense
8.5.4 Recent strategies and developments:
8.5.4.1 Approvals and Trials:
8.6 Biocon Limited
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Approvals and Trials:
8.7 Gan & Lee Pharmaceuticals
8.7.1 Company Overview
8.7.2 Financial Analysis
8.8 Geropharm LLC
8.8.1 Company Overview
8.9 Wockhardt Ltd.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. MannKind Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent strategies and developments:
8.10.4.1 Acquisition and Mergers:
8.10.4.2 Partnerships, Collaborations, and Agreements:
TABLE 1 Europe Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 2 Europe Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Rapid Acting Insulin Market]
TABLE 4 Product Launches And Product Expansions– Rapid Acting Insulin Market
TABLE 5 Acquisition and Mergers– Rapid Acting Insulin Market
TABLE 6 Approvals and Trials– Rapid Acting Insulin Market
TABLE 7 Europe Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 8 Europe Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 9 Europe Insulin Lispro Market by Country, 2017 - 2020, USD Million
TABLE 10 Europe Insulin Lispro Market by Country, 2021 - 2027, USD Million
TABLE 11 Europe Insulin Aspart Market by Country, 2017 - 2020, USD Million
TABLE 12 Europe Insulin Aspart Market by Country, 2021 - 2027, USD Million
TABLE 13 Europe Insulin Glulisine Market by Country, 2017 - 2020, USD Million
TABLE 14 Europe Insulin Glulisine Market by Country, 2021 - 2027, USD Million
TABLE 15 Europe Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 16 Europe Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 17 Europe Type 2 Diabetes Market by Country, 2017 - 2020, USD Million
TABLE 18 Europe Type 2 Diabetes Market by Country, 2021 - 2027, USD Million
TABLE 19 Europe Type 1 Diabetes Market by Country, 2017 - 2020, USD Million
TABLE 20 Europe Type 1 Diabetes Market by Country, 2021 - 2027, USD Million
TABLE 21 Europe Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 22 Europe Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 23 Europe Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 24 Europe Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 25 Europe Drug Stores & Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 26 Europe Drug Stores & Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 27 Europe Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 28 Europe Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 29 Europe Rapid Acting Insulin Market by Country, 2017 - 2020, USD Million
TABLE 30 Europe Rapid Acting Insulin Market by Country, 2021 - 2027, USD Million
TABLE 31 Germany Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 32 Germany Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 33 Germany Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 34 Germany Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 35 Germany Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 36 Germany Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 37 Germany Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 38 Germany Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 39 UK Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 40 UK Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 41 UK Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 42 UK Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 43 UK Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 44 UK Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 45 UK Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 46 UK Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 47 France Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 48 France Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 49 France Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 50 France Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 51 France Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 52 France Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 53 France Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 54 France Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 55 Russia Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 56 Russia Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 57 Russia Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 58 Russia Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 59 Russia Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 60 Russia Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 61 Russia Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 62 Russia Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 63 Spain Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 64 Spain Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 65 Spain Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 66 Spain Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 67 Spain Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 68 Spain Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 69 Spain Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 70 Spain Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 71 Italy Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 72 Italy Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 73 Italy Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 74 Italy Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 75 Italy Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 76 Italy Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 77 Italy Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 78 Italy Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 79 Rest of Europe Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 80 Rest of Europe Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 81 Rest of Europe Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 82 Rest of Europe Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 83 Rest of Europe Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 84 Rest of Europe Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 85 Rest of Europe Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 86 Rest of Europe Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 87 key information - Merck & Co., Inc.
TABLE 88 Key Information – Sanofi S.A.
TABLE 89 Key information – Novo Nordisk A/S
TABLE 90 Key Information – Eli Lilly and Company
TABLE 91 key information – Adocia SA
TABLE 92 Key Information – Biocon Limited
TABLE 93 Key Information – Gan & Lee Pharmaceuticals
TABLE 94 key Information – Geropharm LLC
TABLE 95 Key Information – Wockhardt Ltd.
TABLE 96 Key Information – MannKind Corporation

List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 4 Recent strategies and developments: Novo Nordisk A/S
FIG 5 Recent strategies and developments: Eli Lilly and Company
FIG 6 Recent strategies and developments: MannKind Corporation

Purchase Full Report of
Europe Rapid Acting Insulin Market

Buy Now

Avail up to 60% discount on subscription plans on

SUBSCRIPTION MODEL